Literature DB >> 21652586

Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study.

Amelia Ruffatti1, Marta Tonello, Maria S Visentin, Agnese Bontadi, Ariela Hoxha, Sara De Carolis, Angela Botta, Silvia Salvi, Monica Nuzzo, Patrizia Rovere-Querini, Valentina Canti, Marta Mosca, Gorana Mitic, Maria T Bertero, Vittorio Pengo, Marie C Boffa, Angela Tincani.   

Abstract

OBJECTIVE: To identify the risk factors associated with pregnancy failure in patients with APS treated with conventional therapy.
METHODS: A multicentre, case-control study was conducted to compare APS patients with successful and unsuccessful pregnancy outcomes. We retrospectively considered 410 pregnancies of women diagnosed with primary APS. The study focused on 57 unsuccessful pregnancies (considered the study population) and 57 successful pregnancies (considered the control population) matched for age and therapy. All the patients had been treated with conventional protocol treatments including low-dose aspirin and/or heparin. The clinical and laboratory features of the two groups of women diagnosed with APS were compared.
RESULTS: The independent risk factors for pregnancy failure were: (i) the presence of SLE or other autoimmune diseases [odds ratio (OR) 6.0; 95% CI 1.7, 20.8; P = 0.01]; (ii) history of both thrombosis and pregnancy morbidity (OR 12.1; 95% CI 1.3, 115.3; P = 0.03); and (iii) triple [Immunoglobulin (Ig) G/IgM aCLs plus IgG/IgM anti-β(2) glycoprotein I antibodies plus LA] aPL positivity (OR 4.1; 95% CI 1.0, 16.7; P = 0.05). APS patients diagnosed on the basis of a single positive test and/or history of pregnancy morbidity alone were generally found to have successful pregnancies.
CONCLUSION: It would seem from these findings that the risk of pregnancy failure in APS women planning to conceive can be stratified on the basis of some specific clinical and laboratory features.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652586     DOI: 10.1093/rheumatology/ker139

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  40 in total

1.  ApoE Receptor 2 Mediation of Trophoblast Dysfunction and Pregnancy Complications Induced by Antiphospholipid Antibodies in Mice.

Authors:  Jane E Salmon; Chieko Mineo; Victoria Ulrich; Shari E Gelber; Milena Vukelic; Anastasia Sacharidou; Joachim Herz; Rolf T Urbanus; Philip G de Groot; David R Natale; Anirudha Harihara; Patricia Redecha; Vikki M Abrahams; Philip W Shaul
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

2.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

3.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Authors:  Michael D Lockshin; Mimi Kim; Carl A Laskin; Marta Guerra; D Ware Branch; Joan Merrill; Michelle Petri; T Flint Porter; Lisa Sammaritano; Mary D Stephenson; Jill Buyon; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-07

Review 4.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

5.  Top 10 clinical research developments in antiphospholipid syndrome.

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

Review 6.  Management of recurrent thrombosis in antiphospholipid syndrome.

Authors:  Cecilia Nalli; Laura Andreoli; Cinzia Casu; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2014-03       Impact factor: 4.592

Review 7.  [Antiphospholipid syndrome].

Authors:  C Specker
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 8.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

Review 9.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 10.  Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy.

Authors:  Michael D Lockshin
Journal:  Clin Lab Med       Date:  2013-04-19       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.